Estimating the long-term cost-effectiveness of exenatide in the United States: An adjunctive treatment for type 2 diabetes mellitus

Value in Health

Volumn 11, Issue 1, 2008, Pages 22-33

  Minshall, Michael E ^a   Oglesby, Alan K ^b   Wintle, Matthew E ^c   Valentine, William J ^a   Roze, Stéphane ^a   Palmer, Andrew J ^a  

^a IQVIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

BYETTA; Cost effectiveness; Exenatide; Modeling; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BECAPLERMIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; SIMVASTATIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNITED STATES;

EID: 38549104931     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00211.x     Document Type: Article

References (57)

1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003 46 : 3 19.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006 29 : S43 8.
3. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998 40 : S21 5.
4. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995 122 : 481 6.
5. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003 22 : 331 9.
6. Bosello O, Armellini F, Zamboni M, Fitchet M. The benefits of modest weight loss in Type II diabetes. Int J Obes Relat Metab Disord 1997 21 : S10 3.
7. National Institutes of Health. Consensus development conference on diet and exercise in non-insulin-dependent diabetes mellitus. Diabetes Care 1987 10 : 639 44.
8. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006 49 : 1711 21.
9. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999 131 : 281 303.
10. Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care 2005 28 : 59 64.
11. Garber AJ. Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. Diabetes Obes Metab 2002 4 : S5 12.
12. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to Type 2 Diabetes. Diabetes Care 1997 20 : 1744 66.
13. Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002 162 : 1867 72.
14. Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complications 2005 19 : 113 22.
15. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003 26 : 917 32.
16. Academy of Managed Care Pharmacy. The AMCP format for formulary submissions. April, 2005, Version 2.1.
17. Triplitt C, Chiquette E. Exenatide: from the Gila monster to the pharmacy. J Am Pharm Assoc 2006 46 : 44 55.
18. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005 28 : 1092 100.
19. Edwards CMB, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001 281 : E155 61.
20. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulphonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 27 : 2628 35.
21. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 28 : 1083 91.
22. BYETTA (exenatide) injection prescribing information. Amylin Pharmaceuticals, Inc. 2007.
23. Kendall DM, Kim DD, Poon T, et al. Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 weeks. Diabetes 2005 54 (Suppl. 1 A4 5.
24. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006 8 : 436 47.
25. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003 163 : 1637 41.
26. American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004 27 : 2262 5.
27. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004 20 : S5 26.
28. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004 20 : S27 40.
29. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 86.
30. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
31. Buse JB, Klonoff DC, Nielsen LL, et al. Effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes. Clin Ther 2007 29 : 139 53.
32. CPI Inflation Calculator. Available from: http://data.bls.gov/cgi-bin/ cpicalc.pl [Accessed September 1, 2005].
33. Jonsson B CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002 45 : S5 12. Epub 2002 May 24.
34. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005 14 : 217 30.
35. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY : Oxford University Press, 1996.
36. Hunink MG, Bult JR, de Vries J, Weinstein MC. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998 18 : 337 46.
37. American Diabetes Association. Guidelines for computer modelling of diabetes and its complications. Diabetes Care 2004 27 : 2262 5.
38. Mark DB, Simons TA. Fundamentals of economic analysis. Am Heart J 1999 137 : S38 40.
39. Wintle M, Bhole D, Mac S, et al. Improvements in cardiovascular risk factors accompanied improved glycaemia and weight reduction in a european population of patients with type 2 diabetes treated with open-label exenatide for 25 y. Diabetic Med 2006 23 (Suppl 4 P 1538.
40. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005 54 : 1 7.
41. Harris MI, Cowie CC, Stern MP. Diabetes in America (2nd ed.). Bethesda, MD : National Institute of Diabetes and Digestive and Kidney Diseases, 1995. Report no. 95-1468 (NIH publication no. 95-1468).
42. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001 24 : 1614 9.
43. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998 82 : 2N 9.
44. Phillips SJ, Whisnant JP, O'Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990 65 : 344 59.
45. Miller CD, Phillips LS, Tate MK, et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000 23 : 444 8.
46. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000 23 : 754 8.
47. Brändle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003 26 : 2300 4.
48. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992 152 : 610 16.
49. Benett IJ, Lambert C, Hinds G, Kirton C. Emerging standards for diabetes care from a city-wide primary care audit. Diabet Med 1994 11 : 489 92.
50. Massing MW, Foley KA, Sueta CA, et al. Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves? Diabetes Care 2003 26 : 991 7.
51. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002 25 : 718 23.
52. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003 25 : 1017 38.
53. DRG Guidebook. A Comprehensive Resource to the DRG Classification System (17th ed.). Eden Prairie, MN : St. Anthony Publishing, 2001.
54. Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care 2003 26 : 2305 10.
55. Fleming T (Ed). Medical Economics Company. Drug Topics Red Book. Montvale, NJ : Medical Economics Company, 2000.
56. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999 131 : 660 7.
57. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001 27 : 347 51.